Atea Pharmaceuticals Stock Analysis

AVIR -  USA Stock  

USD 6.58  0.14  2.17%

The latest Atea Pharmaceuticals price fall could raise concerns from retail investors as the firm it trading at a share price of 6.58 on 1,290,814 in volume. The company executives were unable to exploit market volatilities in December. However, diversifying your overall positions with Atea Pharmaceuticals can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.63. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Atea Pharmaceuticals partners.
Please continue to Trending Equities.

Atea Pharmaceuticals Stock Analysis 

 
Refresh
The Atea Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Atea Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Atea Pharmaceuticals Stock analysis module also helps to analyze the Atea Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Atea Pharmaceuticals Stock Analysis Notes

About 18.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.94. Some equities with similar Price to Book (P/B) outperform the market in the long run. Atea Pharmaceuticals next dividend is scheduled to be issued on the 9th of November 2012. The entity had 1:6 split on the 9th of November 2012. Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people. For more info on Atea Pharmaceuticals please contact Joseph Patti at 678 221-3343 or go to www.aviragentherapeutics.com.

Atea Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Atea Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Atea Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Atea Pharmaceuticals generated a negative expected return over the last 90 days
Atea Pharmaceuticals has high historical volatility and very poor performance
Atea Pharmaceuticals has a poor financial position based on the latest SEC disclosures
Over 76.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.marketscreener.com: Bronstein, Gewirtz Grossman, LLC Notifies Shareholders of Atea Pharmaceuticals, Inc. Investigation - marketscreener.com

Atea Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Atea Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Atea Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report29th of March 2022
Next Earnings Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End29th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Atea Pharmaceuticals Largest EPS Surprises

Earnings surprises can significantly impact Atea Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-08-12
2021-06-300.00450.020.0155344 
2021-11-11
2021-09-30-0.0525-0.34-0.2875547 
2021-05-13
2021-03-31-0.05420.340.3942727 
View All Earnings Estimates

Atea Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Atea Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Atea Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Atea Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
10th of January 2022
Financial Statements and Exhibits. Regulation FD Disclosure
View
10th of December 2021
Unclassified Corporate Event
View
26th of November 2021
Regulation FD Disclosure
View
16th of November 2021
Termination of a Material Definitive Agreement
View
12th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
24th of September 2021
Unclassified Corporate Event
View
3rd of September 2021
Unclassified Corporate Event
View
12th of August 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Atea Pharmaceuticals Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Atea Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Atea Pharmaceuticals backward and forwards among themselves. Atea Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Atea Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Russell Investments Group LtdCommon Shares165 K1.5 M
Diversified Trust CoCommon Shares17 K152 K
Cutler Group LpPut Options19.2 K75 K
Cutler Group LpCommon Shares7.6 K68 K
Cutler Group LpCall Options31.7 K12 K
Edge Wealth Management LlcCommon Shares500K
Parallel Advisors LlcCommon Shares35.00.0
Lindbrook Capital LlcCommon Shares50.00.0
Fmr LlcCommon Shares12.4 M435.3 M
Note, although Atea Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Atea Pharmaceuticals Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 546.82 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Atea Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Atea Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Atea Pharmaceuticals Profitablity

Atea Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Atea Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Atea Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Atea Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Atea Pharmaceuticals' profitability requires more research than a typical breakdown of Atea Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 11.89 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 18.21 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.18.
Last ReportedProjected for 2022
Return on Investment(18.80) (20.28) 
Return on Average Assets(0.0287) (0.031) 
Return on Average Equity(0.0396) (0.0406) 
Return on Invested Capital 0.06  0.07 
Return on Sales(0.20) (0.22) 

Management Efficiency

The entity has return on total asset (ROA) of 4.96 % which means that it generated profit of $4.96 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 7.26 %, meaning that it created $7.26 on every $100 dollars invested by stockholders. Atea Pharmaceuticals management efficiency ratios could be used to measure how well atea pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 01/24/2022, Return on Invested Capital is likely to grow to 0.07, while Return on Investment is likely to drop (20.28) . Atea Pharmaceuticals Total Assets are relatively stable at the moment as compared to the past year. Atea Pharmaceuticals reported last year Total Assets of 993.18 Million. As of 01/24/2022, Current Assets is likely to grow to about 1.1 B, while Asset Turnover is likely to drop 0.1.
Last ReportedProjected for 2022
Book Value per Share 29.18  31.48 
Enterprise Value over EBIT(275.40) (297.14) 
Enterprise Value over EBITDA(275.60) (297.36) 
Price to Book Value 5.67  5.64 
Tangible Assets Book Value per Share 46.00  49.63 
Enterprise ValueBB
Tangible Asset Value993.2 M1.1 B

Technical Drivers

As of the 24th of January, Atea Pharmaceuticals shows the risk adjusted performance of (0.047951), and Mean Deviation of 4.12. Atea Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Atea Pharmaceuticals, which can be compared to its rivals. Please confirm Atea Pharmaceuticals standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Atea Pharmaceuticals is priced correctly, providing market reflects its regular price of 6.58 per share. Given that Atea Pharmaceuticals has jensen alpha of (0.22), we suggest you to validate Atea Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.

Atea Pharmaceuticals Price Movement Analysis

The output start index for this execution was thirty-two with a total number of output elements of two hundred seventy-nine. The MESA Adaptive Moving Average indicator adapts to Atea Pharmaceuticals price movement based on the rate change of phase as measured by the Hilbert Transform Discriminator. View also all equity analysis or get more info about mesa adaptive moving average overlap studies indicator.

Atea Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atea Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atea Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Atea Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Atea Pharmaceuticals Predictive Daily Indicators

Atea Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Atea Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Atea Pharmaceuticals Forecast Models

Atea Pharmaceuticals time-series forecasting models is one of many Atea Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Atea Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Atea Pharmaceuticals Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Atea Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Atea Pharmaceuticals shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Atea Pharmaceuticals. By using and applying Atea Pharmaceuticals Stock analysis, traders can create a robust methodology for identifying Atea Pharmaceuticals entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin(75.66) (81.63) 
EBITDA Margin(0.20) (0.22) 
Gross Margin 0.90  0.89 
Profit Margin(0.20) (0.22) 
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase IIIa clinical trial for the treatment of chronic hepatitis C and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Atea Pharmaceuticals to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Equity Forecasting Now

   

Equity Forecasting

Use basic forecasting models to generate price predictions and determine price momentum
All  Next Launch Module
Please continue to Trending Equities. Note that the Atea Pharmaceuticals information on this page should be used as a complementary analysis to other Atea Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Piotroski F Score module to get Piotroski F Score based on binary analysis strategy of nine different fundamentals.

Complementary Tools for Atea Pharmaceuticals Stock analysis

When running Atea Pharmaceuticals price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Is Atea Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atea Pharmaceuticals. If investors know Atea Pharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atea Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.